At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
GHR-LRXdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly
In Brief
A Phase 2 clinical trial evaluating GHR-LRX for Acromegaly. Completed, enrolled 34 participants across 22 sites in 10 countries.
Detailed Summary
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesEstonia, Hungary, Italy, Latvia, Lithuania, Poland, Romania, Russia, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartJan 2021
Primary CompletionJul 2022
Study CompletionMay 2023
TodayJul 2026
First PostedAug 21, 2020
Enrollment StartJan 4, 2021
Primary CompletionJul 15, 2022
Study CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago
Interventions
GHR-LRXdrug
GHR-LRX was administered by SC injection.